肠道病毒与胰岛自身免疫或1型糖尿病风险:检测病毒核酸和蛋白的对照观察性研究的系统综述与Meta分析
该系统综述与Meta分析检索PubMed和Embase至2023年1月1日,纳入60项对照观察性研究共12077名参与者,发现肠道病毒与胰岛自身免疫(OR 2.1)及1型糖尿病(OR 8.0)相关,1型糖尿病确诊后1个月内关联更强(OR 16.2),肠道病毒B与1型糖尿病相关(OR 12.7)。
要点
- 肠道病毒与胰岛自身免疫相关(OR 2.1,95%CI 1.3-3.3)。
- 肠道病毒与1型糖尿病相关(OR 8.0,95%CI 4.9-13.0)。
- 确诊1型糖尿病1个月内检出肠道病毒关联更强(OR 16.2)。
核心结论
- 研究结果强调肠道病毒与胰岛自身免疫或1型糖尿病之间存在关联。
- 数据加强了针对致糖尿病肠道病毒类型(尤其是肠道病毒B)开发疫苗的理由。
- 需要进行生命早期前瞻性研究,以阐明肠道病毒感染时间、类型和持续时间在启动胰岛自身免疫和进展为1型糖尿病中的作用。
研究设计与样本
- 系统综述与Meta分析,检索PubMed和Embase从建库至2023年1月1日的对照观察性研究。
- 纳入标准为在胰岛自身免疫或1型糖尿病结局个体中检测到肠道病毒RNA或蛋白的队列或病例对照研究。
- 排除妊娠期研究或其他类型糖尿病研究。
- 最终纳入60项研究(40项1型糖尿病、9项胰岛自身免疫、11项两者兼有),共12077名参与者(5981例病例,6096名对照)。
- 研究质量采用纽卡斯尔-渥太华量表和澳大利亚国家健康与医学研究理事会证据等级评估。
主要发现
- 56项研究的Meta分析显示肠道病毒与胰岛自身免疫相关(OR 2.1,95%CI 1.3-3.3;p=0.002;n=18;异质性χ2/df 2.69;p=0.0004;I2=63%)。
- 肠道病毒与1型糖尿病相关(OR 8.0,95%CI 4.9-13.0;p<0.0001;n=48;χ2/df 6.75;p<0.0001;I2=85%)。
- 1型糖尿病确诊1个月内检出肠道病毒关联更强(OR 16.2,95%CI 8.6-30.5;p<0.0001;n=28;χ2/df 3.25;p<0.0001;I2=69%)。
- 检出多种或连续肠道病毒与胰岛自身免疫相关(OR 2.0,95%CI 1.0-4.0;p=0.050;n=8)。
- 检出肠道病毒B与1型糖尿病相关(OR 12.7,95%CI 4.1-39.1;p<0.0001;n=15)。
关键数值与推荐
- 肠道病毒与胰岛自身免疫的合并OR为2.1(95%CI 1.3-3.3;p=0.002;n=18;I2=63%)。
- 肠道病毒与1型糖尿病的合并OR为8.0(95%CI 4.9-13.0;p<0.0001;n=48;I2=85%)。
- 1型糖尿病确诊1个月内检出肠道病毒的合并OR为16.2(95%CI 8.6-30.5;p<0.0001;n=28;I2=69%)。
- 多种或连续肠道病毒与胰岛自身免疫的合并OR为2.0(95%CI 1.0-4.0;p=0.050;n=8)。
- 肠道病毒B与1型糖尿病的合并OR为12.7(95%CI 4.1-39.1;p<0.0001;n=15)。
临床怎么用
- 作者认为数据加强了针对致糖尿病肠道病毒类型(尤其是肠道病毒B)开发疫苗的理由。
- 作者提出需要进行生命早期前瞻性研究,以阐明肠道病毒感染时间、类型和持续时间在启动胰岛自身免疫和进展为1型糖尿病中的作用。
局限性
- 研究设计和质量存在差异,产生了显著的统计异质性(胰岛自身免疫分析I2=63%;1型糖尿病分析I2=85%;1型糖尿病1个月内分析I2=69%)。
- 作者提出需要进行生命早期前瞻性研究,以阐明肠道病毒感染时间、类型和持续时间在启动胰岛自身免疫和进展为1型糖尿病中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enteroviruses are routinely detected with molecular methods within large cohorts that are at risk of type 1 diabetes. We aimed to examine the association between enteroviruses and either islet autoimmunity or type 1 diabetes. METHODS: For this systematic review and meta-analysis, we searched PubMed and Embase for controlled observational studies from inception until Jan 1, 2023. Cohort or case-control studies were eligible if enterovirus RNA or protein were detected in individuals with outcomes of islet autoimmunity or type 1 diabetes. Studies in pregnancy or other types of diabetes were excluded. Data extraction and appraisal involved author contact and deduplication, which was done independently by three reviewers. Study quality was assessed with the Newcastle-Ottawa Scale and National Health and Medical Research Council levels of evidence. Pooled and subgroup meta-analyses were done in RevMan version 5.4, with random effects models and Mantel-Haenszel odds ratios (ORs; 95% CIs). The study is registered with PROSPERO, CRD42021278863. FINDINGS: The search returned 3266 publications, with 897 full texts screened. Following deduplication, 113 eligible records corresponded to 60 studies (40 type 1 diabetes; nine islet autoimmunity; 11 both), comprising 12077 participants (5981 cases; 6096 controls). Study design and quality varied, generating substantial statistical heterogeneity. Meta-analysis of 56 studies showed associations between enteroviruses and islet autoimmunity (OR 2·1, 95% CI 1·3-3·3; p=0·002; n=18; heterogeneity χ2/df 2·69; p=0·0004; I2=63%), type 1 diabetes (OR 8·0, 95% CI 4·9-13·0; p<0·0001; n=48; χ2/df 6·75; p<0·0001; I2=85%), or within 1 month of type 1 diabetes (OR 16·2, 95% CI 8·6-30·5; p<0·0001; n=28; χ2/df 3·25; p<0·0001; I2=69%). Detection of either multiple or consecutive enteroviruses was associated with islet autoimmunity (OR 2·0, 95% CI 1·0-4·0; p=0·050; n=8). Detection of Enterovirus B was associated with type 1 diabetes (OR 12·7, 95% CI 4·1-39·1; p<0·0001; n=15). INTERPRETATION: These findings highlight the association between enteroviruses and islet autoimmunity or type 1 diabetes. Our data strengthen the rationale for vaccine development targeting diabetogenic enterovirus types, particularly those within Enterovirus B. Prospective studies of early life are needed to elucidate the role of enterovirus timing, type, and infection duration on the initiation of islet autoimmunity and the progression to type 1 diabetes. FUNDING: Environmental Determinants of Islet Autoimmunity, European Association for the Study of Diabetes, JDRF, Australian National Health and Medical Research Council, and University of New South Wales.
引用
- Isaacs SR, Roy A, Dance B, et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol. 2023. PMID: 37390839. doi:10.1016/S2213-8587(23)00122-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。